Solid biosciences reports inducement grants under nasdaq listing rule 5635(c)(4)

Charlestown, mass., dec. 05, 2022 (globe newswire) -- solid biosciences inc. (nasdaq: sldb), a life sciences company focused on advancing meaningful therapies for patients with neuromuscular and cardiac diseases, today announced the grant of inducement awards to its newly appointed president and chief executive officer, alexander (bo) cumbo; chief administrative officer, david tyronne howton; chief scientific officer, friedreich's ataxia and cardiac pipeline, jennifer marlowe, ph.d.; chief regulatory officer, jessie hanrahan, ph.d.; and chief technology officer, paul herzich. the grants were approved by the company's board of directors as an inducement material to each of mr. cumbo, mr. howton, dr. marlowe, dr. hanrahan and mr. herzich entering into employment with the company in accordance with nasdaq listing rule 5635(c)(4). mr. cumbo received an inducement grant with an option to purchase up to 228,900 shares of common stock as well as a restricted stock unit (rsu) award of 114,449 shares of common stock. mr. howton received an inducement grant with an option to purchase up to 104,410 shares of common stock as well as an rsu award of 52,205 shares of common stock. dr. marlowe received an inducement grant with an option to purchase up to 95,110 shares of common stock as well as an rsu award of 47,555 shares of common stock. dr. hanrahan received an inducement grant with an option to purchase up to 94,899 shares of common stock as well as an rsu award of 47,449 shares of common stock. mr. herzich received an inducement grant with an option to purchase up to 57,900 shares of common stock as well as an rsu award of 28,955 shares of common stock.
SLDB Ratings Summary
SLDB Quant Ranking